Bifeprunox doses for treating schizophrenia

The present disclosure is directed to a daily dose of bifeprunox for the treatment of a patient with schizophrenia. Such dose is effectively used in methods for treating schizophrenia comprising administering to a patient a pharmaceutical composition comprising an effective amount of at least one bi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	NATHAN A. SHAPIRA, SANGEETA RAJE, DORTE MALLING, ROSELINE PARDUE, JETTE BUCH OSTERGARD, JEFF PAUL, MARC DEBELLE, ANTJE A. WINSEMIUS, PAUL P. YEUNG, JENS HEISTERBERG, STEVEN G. POTKIN, LUIGI M. BARBATO, MICHEL BOURIN, DANIEL E. CASEY, ELLEN B. CHRISTENSEN, JOHN NEWCOMER, SAEED AHMED, MICHIEL H. DE VRIES, MARK RAPAPORT, METTE KROG JOSIASSEN
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure is directed to a daily dose of bifeprunox for the treatment of a patient with schizophrenia. Such dose is effectively used in methods for treating schizophrenia comprising administering to a patient a pharmaceutical composition comprising an effective amount of at least one bifeprunox compound, amongst other effects, resulting in a reduction of side effects associated with schizophrenia treatment such as: no weight gain, improvement of non-fasting triglyceride levels and/or total cholesterol levels. Treatment effects are e.g. a reduction of PANSS total score in a patient and an increase of the time to deterioration of schizophrenia and improvement of psychotic symptoms.